1. Home
  2. KWR vs BEATW Comparison

KWR vs BEATW Comparison

Compare KWR & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KWR
  • BEATW
  • Stock Information
  • Founded
  • KWR 1918
  • BEATW 2015
  • Country
  • KWR United States
  • BEATW United States
  • Employees
  • KWR N/A
  • BEATW N/A
  • Industry
  • KWR Major Chemicals
  • BEATW Retail: Computer Software & Peripheral Equipment
  • Sector
  • KWR Industrials
  • BEATW Technology
  • Exchange
  • KWR Nasdaq
  • BEATW Nasdaq
  • Market Cap
  • KWR N/A
  • BEATW N/A
  • IPO Year
  • KWR 1985
  • BEATW N/A
  • Fundamental
  • Price
  • KWR $141.68
  • BEATW $0.57
  • Analyst Decision
  • KWR Buy
  • BEATW
  • Analyst Count
  • KWR 3
  • BEATW 0
  • Target Price
  • KWR $177.33
  • BEATW N/A
  • AVG Volume (30 Days)
  • KWR 129.2K
  • BEATW 4.7K
  • Earning Date
  • KWR 02-24-2025
  • BEATW 03-14-2025
  • Dividend Yield
  • KWR 1.37%
  • BEATW N/A
  • EPS Growth
  • KWR 647.22
  • BEATW N/A
  • EPS
  • KWR 6.82
  • BEATW N/A
  • Revenue
  • KWR $1,862,709,000.00
  • BEATW N/A
  • Revenue This Year
  • KWR N/A
  • BEATW N/A
  • Revenue Next Year
  • KWR $1.95
  • BEATW N/A
  • P/E Ratio
  • KWR $20.76
  • BEATW N/A
  • Revenue Growth
  • KWR N/A
  • BEATW N/A
  • 52 Week Low
  • KWR $124.66
  • BEATW $0.50
  • 52 Week High
  • KWR $207.83
  • BEATW $0.62
  • Technical
  • Relative Strength Index (RSI)
  • KWR 52.38
  • BEATW N/A
  • Support Level
  • KWR $139.44
  • BEATW N/A
  • Resistance Level
  • KWR $139.46
  • BEATW N/A
  • Average True Range (ATR)
  • KWR 3.85
  • BEATW 0.00
  • MACD
  • KWR 0.81
  • BEATW 0.00
  • Stochastic Oscillator
  • KWR 63.43
  • BEATW 0.00

About BEATW Heartbeam Inc.

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: